ABBV - AbbVie - Stock Price & Dividends

AbbVie Inc. is a multinational pharmaceutical company that engages in the discovery, development, production, and distribution of a wide range of medications globally. The company's product portfolio includes treatments for various autoimmune diseases, such as Humira, which is used to treat conditions like rheumatoid arthritis, Crohn's disease, and psoriasis.

AbbVie also offers several other notable medications, including Skyrizi, which is used to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease. Additionally, the company provides Rinvoq, a treatment for rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease. Furthermore, AbbVie's portfolio includes Imbruvica, a medication used to treat adult patients with certain types of blood cancers.

Other notable products in AbbVie's portfolio include Epkinly, which is used to treat lymphoma; Elahere, a cancer treatment; and Venclexta/Venclyxto, a medication used to treat certain types of blood cancers. The company also offers a range of aesthetic products, including facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Moreover, AbbVie provides Botox therapeutic, a medication used to treat various conditions, including facial wrinkles and spasms.

In the field of neuroscience, AbbVie offers several treatments, including Vraylar, a medication used to treat depressive disorder; Duopa and Duodopa, which are used to treat advanced Parkinson's disease; Ubrelvy, an acute treatment for migraine in adults; and Qulipta, a medication used to treat episodic and chronic migraine. The company also provides a range of eye care products, including Ozurdex, which is used to treat eye diseases; Lumigan/Ganfort and Alphagan/Combigan, which are used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension; and Restasis, a medication used to increase tear production.

AbbVie's portfolio also includes several other medications, such as Mavyret/Maviret, which is used to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron, a medication used to treat advanced prostate cancer, endometriosis, and central precocious puberty; Linzess/Constella, a treatment for irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid, a medication used to treat hypothyroidism.

The company has established several collaborations with other pharmaceutical companies, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., and Genentech, Inc. AbbVie has also partnered with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. Founded in 2012, AbbVie is headquartered in North Chicago, Illinois.